Malaysia in Focus: Reverse Cardiac Remodelling

Published: 11 March 2021

  • Views:

    Views Icon 326
  • Likes:

    Heart Icon 1

Overview

Full programme

  • Views:

    Views Icon 326
  • Likes:

    Heart Icon 1

Overview

This reverse cardiac remodelling IME programme brings together a leading faculty of internationally-recognised experts, combining presentations and peer-to-peer discussions to provide comprehensive overview of the latest data and opinion around cardiac remodelling.

Beyond the global focus, this programme also seeks – through insight from Dato' Dr David Chew – to frame and contextualise the topics discussed with specific focus on Malaysia, to help support the education of local physicians on pertinent topics including guideline adherence, emerging data, and best practice.

 
This independent medical education programme is supported by an unrestricted educational grant from Novartis. The programme has been endorsed by the National Heart Association of Malaysia (NHAM).

Learning Objectives

  • Define cardiac remodelling, with particular focus on the influence of cardiovascular damage, pathogenic risk factors and the structural and functional changes in the left ventricle.
  • List the main clinical implications of cardiac remodelling.
  • Summarise the relationship between circulating biomarkers, such as NT-proBNP, troponin and sST2, with the extent left ventricular remodelling in subjects with HF.
  • Interpret the most recent clinical data from pharmacological and device-based studies in HFrEF and HfpEF.
  • Recall the evidence for reverse cardiac remodelling brought about through ARNi therapy, including (but not limited to) PROVE-HF and EVALUATE-HF.
  • Review real-world insight into the impact that ARNi therapy has on cardiac reverse remodelling.

Audience

  • Practicing cardiologists
  • Heart failure specialists
  • Health care professionals involved in the diagnosis and management of patients with heart failure

Series overview

Part 1

Recognising and Treating Cardiac Remodelling in Heart Failure

1 session

  • Recognising and Treating Cardiac Remodelling in Heart Failure

    Watch now

Part 2

The Clinical Implications of Cardiac Remodelling in Heart Failure

1 session

  • The Clinical Implications of Cardiac Remodelling in Heart Failure

    Watch now

Part 3

Relationships of Cardiac Biomarkers

1 session

  • Relationships of Cardiac Biomarkers

    Watch now

Part 4

Prevalence of HFpEF on the Rise – Treat HFpEF as a Whole, Not Just the Comorbidities

1 session

  • Prevalence of HFpEF on the Rise – Treat HFpEF as a Whole, Not Just the Comorbidities

    Watch now

Part 5

ARNI: PARAMOUNT, PARAGON-HF, PARALLAX and Putative Placebo Analysis

1 session

  • ARNI: PARAMOUNT, PARAGON-HF, PARALLAX and Putatuve Placebo Analysis

    Watch now

Part 6

Overview of the Evidence

1 session

Part 7

Angiotensin Receptor Neprilysin Inhibitors – Renal Safety and Efficacy

1 session

  • Angiotensin Receptor Neprilysin Inhibitors – Renal Safety and Efficacy

    Watch now

Faculty biographies